AGEN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Agenus Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK, Sept. 11, 2024 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Agenus Inc. ("Agenus" or "the Company") (NASDAQ: AGEN) and certain of its officers.
Class DefinitionThis lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Agenus securities between January 23, 2023, and July 17, 2024, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/AGEN.
Case DetailsThe Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, the Complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that: (1) the combination therapy of botensilimab and balstilimab was less effective than Defendants had led investors to believe; (2) accordingly, botensilimab and balstilimab's clinical results, as well as their regulatory and commercial prospects, were overstated; and (3) as a result, the Company's public statements were materially false and misleading at all relevant times.
What's Next?A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: bgandg.com/AGEN or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffered a loss in Agenus you have until November 5, 2024, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.
There is No Cost to YouWe represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & GrossmanBronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
ContactBronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | info@bgandg.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/agen-investor-alert-bronstein-gewirtz--grossman-llc-announces-that-agenus-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit-302243991.html
SOURCE Bronstein, Gewirtz & Grossman, LLC
Ausgewählte Hebelprodukte auf Agenus
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Agenus
Der Hebel muss zwischen 2 und 20 liegen
Aktuelle Agenus Aktie News
Agenus Analysen
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Agenus nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen
| Datum | Rating | Analyst | |
|---|---|---|---|
| 22.04.19 | Agenus Buy | B. Riley FBR | |
| 28.10.16 | Agenus Neutral | H.C. Wainwright & Co. | |
| 27.10.16 | Agenus Buy | Maxim Group | |
| 11.03.16 | Agenus Buy | Maxim Group | |
| 27.10.15 | Agenus Hold | Maxim Group |
